First-line (1L) treatment of follicular lymphoma (FL) with atezolizumab and obinutuzumab (A plus O) plus /- radiotherapy (RT): Results from the FLUORO study

被引：0
|
作者：
Chong, Geoffrey
Lee, Denise
Lee, Sze Ting
Grobler, Anneke
Khor, Richard
Campbell, Belinda A.
Thachil, Thanuja
Manos, Kate
Martynchyk, Arina
Douglas, Genevieve
Keane, Colm
Palmer, Jodie
Hawkes, Eliza Anne
机构：
[1] Grampians Hlth, Ballarat, Vic, Australia
[2] Eastern Hlth, Box Hill, Vic, Australia
[3] Austin Hlth, Dept Mol Imaging & Therapy, Heidelberg, Vic, Australia
[4] Univ Melbourne, Melbourne, Vic, Australia
[5] Olivia Newton John Canc Res Inst, Melbourne, Australia
[6] La Trobe Univ, Melbourne, Vic, Australia
[7] Murdoch Childrens Res Inst, Parkville, Vic, Australia
[8] Austin Hlth, Austin, Australia
[9] Peter MacCallum Canc Ctr, Melbourne, Australia
[10] Grampians Hlth, Ballarat, Vic, Australia
[11] Flinders Med Ctr, Adelaide, SA, Australia
[12] Univ Queensland, Frazer Inst, Brisbane, Qld, Australia
[13] Olivia NewtonJohn Canc Wellness & Res Ctr, Heidelberg, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7070
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Frontline treatment of follicular lymphoma with atezolizumab and obinutuzumab, with and without radiotherapy (The FLUORO study).
    Hawkes, Eliza Anne
    Manos, Kate
    Khor, Richard
    Douglas, Genevieve
    Lee, Sze Ting
    Lee, Denise
    Campbell, Belinda
    Grobler, Anneke
    Gilbertson, Michael
    Palmer, Jodie
    Chong, Geoff
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [2] RADIOTHERAPY PLUS RITUXIMAB AS FIRST-LINE REGIMEN FOR LOCALIZED FOLLICULAR LYMPHOMA
    Cencini, E.
    Puccini, B.
    Rigacci, L.
    Fabbri, A.
    Kovalchuk, S.
    Mannelli, L.
    Benelli, G.
    Carfagno, T.
    Simontacchi, G.
    Bocchia, M.
    Bosi, A.
    HAEMATOLOGICA, 2017, 102 : 108 - 109
  • [3] Radiotherapy plus rituximab as first-line regimen for localized follicular lymphoma
    Cencini, Emanuele
    Puccini, Benedetta
    Rigacci, Luigi
    Fabbri, Alberto
    Kovalchuk, Sofia
    Mannelli, Lara
    Benelli, Gemma
    Carfagno, Tommaso
    Simontacchi, Gabriele
    Bocchia, Monica
    Bosi, Alberto
    LEUKEMIA & LYMPHOMA, 2018, 59 (06) : 1420 - 1426
  • [4] Healthcare Resource Utilization and Costs Associated with Obinutuzumab Plus Bendamustine Versus Rituximab Plus Bendamustine for First-Line Treatment of Follicular Lymphoma
    To, Tu My
    Ta, Jamie T.
    Seetasith, Arpamas
    Wang, Rongrong
    Lai, Dominic
    Shapouri, Sheila
    BLOOD, 2021, 138
  • [5] Obinutuzumab Plus Chemotherapy As First Line Treatment in Patients with Follicular Lymphoma: Experience from a Community Hospital
    de Una, Soraya Lorente
    Gutierrez, Javier
    Gonzalez, Matilde
    Kumar, Anjana
    Morales, Elena
    Herrada, Juan
    BLOOD, 2022, 140 : 12001 - 12001
  • [6] Pelareorep (pela) plus atezolizumab (atezo) and chemotherapy in first-line (1L) advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) patients: Results from the GOBLET study
    Arnold, D.
    Goekkurt, E.
    Stein, A.
    Martens, U. M.
    Chater, J.
    Ungerechts, G.
    Loghmani, H.
    Coffey, M.
    Trauger, R.
    Heineman, T. C.
    ANNALS OF ONCOLOGY, 2023, 34 : S899 - S899
  • [7] A multicenter randomized trial of Fludarabine and Mitoxantrone (FM) plus Rituximab versus CHOP plus Rituximab as first-line treatment in patients with follicular lymphoma (FL).
    Zinzani, PL
    BLOOD, 2002, 100 (11) : 93A - 93A
  • [8] Ibrutinib plus Obinutuzumab Versus Chlorambucil plus Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results from Phase 3 iLLUMINATE
    Moreno, Carol
    Greil, Richard
    Demirkan, Fatih
    Tedeschi, Alessandra
    Anz, Bertrand
    Larratt, Loree
    Simkovic, Martin
    Samoilova, Olga
    Novak, Jan
    Ben-Yehuda, Dina
    Strugov, Vladimir
    Gill, Devinder
    Gribben, John G.
    Hsu, Emily
    Zhou, Cathy
    Clow, Fong
    James, Danelle F.
    Styles, Lori
    Flinn, Ian W.
    BLOOD, 2018, 132
  • [9] First-line treatment of follicular lymphoma (FL) with golcadamide, rituximab plus /- nivolumab: An umbrella randomised phase 2 investigator-led study.
    Chong, Geoffrey
    Palmer, Jodie
    Barraclough, Allison
    Churilov, Leonid
    Keane, Colm
    Lee, Sze Ting
    Lee, Denise
    Ratnasingam, Sumita
    Smith, Charmaine
    Hawkes, Eliza Anne
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [10] CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma
    Marcus, R
    Imrie, K
    Belch, A
    Cunningham, D
    Flores, E
    Catalano, J
    Solal-Celigny, P
    Offner, F
    Walewski, J
    Raposo, J
    Jack, A
    Smith, P
    BLOOD, 2005, 105 (04) : 1417 - 1423
12345